Challenges to heart failure medication prescribing post-hospitalization

Author:

Li Jiaqi1ORCID,Sanyu Visopiano2,Coia Elise1,Fernando Romaniya3,Asghari-Jafarabadi Mohammad45,Better Nathan36,Wojnar Robert1

Affiliation:

1. Department of Pharmacy, Cabrini Hospital , Malvern, Melbourne, VIC 3144 , Australia

2. Department of Medicine, Cabrini Hospital , Malvern, Melbourne, VIC 3144 , Australia

3. Department of Cardiology, Cabrini Hospital , Malvern, Melbourne, VIC 3144 , Australia

4. Cabrini Research, Cabrini Health , Malvern, VIC 3144 , Australia

5. School of Public Health and Preventative Medicine, Monash University , Melbourne, VIC 3004 , Australia

6. Department of Medicine, Monash University , Clayton, Melbourne, VIC 3800 , Australia

Abstract

Abstract Objectives To determine the prevalence of heart failure (HF) medication prescribing on discharge post-HF-related admission. Methods A retrospective audit was conducted for 216 HF admissions over a period of 6 months; medication data from electronic records were collected for analysis. Key findings The prevalence of HF medication prescribing on discharge was: 32.9% (95% confidence interval: 26.6–39.6) renin–angiotensin–aldosterone system inhibitors, 10.6% (6.9–15.6) angiotensin receptor-neprilysin inhibitors, 31.5% (25.4–38.1) HF-specific beta-blockers, 42.6% (35.9–49.5) aldosterone receptor antagonists, and 11.6% (7.6–16.6) sodium-glucose cotransporter-2 inhibitors. Conclusion HF medication prescribing remains relatively low despite the known benefits and recommendations listed in the guidelines.

Publisher

Oxford University Press (OUP)

Reference10 articles.

1. Consensus statement on the current pharmacological prevention and management of heart failure;Sindone;Med J Aust,2022

2. Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalisation;Bozkurt;JACC Heart Fail,2023

3. Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting;Al-Omary;Open Heart,2022

4. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines;Heidenreich;Circulation,2022

5. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure;McDonagh;Eur Heart J,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3